How to sell a statin? Pfizer and AstraZeneca have different ideas

Tracy Staton It's a tale of two statin drugs and their attempts to keep market share–or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay ...

UPDATED: Pfizer hikes bid for AstraZeneca to $117B, swears off hostile maneuver

John Carroll Pfizer has upped its bid for AstraZeneca to £55 a share, or $ 117 billion, hitting the "magic number" that bankers close to these talks ...

Pfizer expansion allows it to make drugs for trials at Cork, Ireland, facility

Eric Palmer Pfizer has opened an expanded product technology laboratory at its Ringaskiddy, County Cork, facility. The company has invested about $ 30 million in the lab, Business ...

Pfizer, Novartis and 3 others put an extra $1M each into Q1 lobbying

Eric Palmer Big Pharma companies, like other corporate beings, spend millions on lobbying in Washington, DC. In fact, a handful of companies spent $ 1 million more each in the first ...

Ignoring harsh lessons, Pfizer prepares to pounce on AstraZeneca

John Carroll The Financial Times reported Sunday evening that Pfizer may make a public declaration of its interest in buying out AstraZeneca within days after renewing an overture that ...

As Pfizer Readies New Business Units, Amy Schulman Exits

esilverman Just a few months after Pfizer tapped general counsel Amy Schulman to head one of three so-called innovative business units that are supposed to take shape in January ...

Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Tracy Staton Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? FiercePharma News

Pfizer gives the raspberry to BlackBerry

Eric Palmer Pfizer, which sells the hemophilia drug Xyntha, last year rolled out its HemMobile app to build its relationship with patients who use its treatments. The fact ...

Eli Lilly spells out $1.8B deal to partner with Pfizer on tanezumab

John Carroll When Pfizer first let slip that it struck a deal to collaborate with Eli Lilly on the high-risk anti-NGF pain drug tanezumab, the news was delivered without any of the ...

Pfizer aims ambitious PCSK9 program at payers, skeptical regulators

Tracy Staton Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs ...

Pfizer exec Amy Schulman talks gender, power and company policy

Tracy Staton Soon to lead a new vaccines, oncology and consumer health division at Pfizer, Schulman says ambitious women need to speak up, spend their political capital and stop ...

Psoriasis study does little to help Pfizer with Xeljanz

Carly Helfand Rheumatoid arthritis treatment Xeljanz, while expected to grow into a big seller for Pfizer, hasn't had a fast start. The company hoped adding a psoriasis indication ...
Page 5 of 11« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS